Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin ...

In trading on Thursday, shares of NewAmsterdam Pharma Company N V (Symbol: NAMS) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $19.60 per share.

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. Getting addicted, no pun intended, to an animated conspiracy thriller from Adult Swim ...

19:50 EST Tonix Pharmaceuticals (TNXP) trading halted, news pending Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed ...

Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been assigned an average rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports.

Perform material- and labor-effective extrusion with Thermo Scientific™ Pharma 11 Twin-screw Extruder, which requires only a small amount of active pharmaceutical ingredient, operating at ...

“As we have communicated over the last year, we are focused on strengthening the company’s long-term growth profile,” a BMS spokesperson said in response to Fierce Pharma’s inquiry about t ...

Way back in the early days of the pharmaceutical industry, the first medicines were derived from well-known food supplements or herbal remedies. Over time, the concept of a “medicine” has been ...

The Swedish pharmaceutical pricing agency could decline to reimburse medication for a common disease. The new refusal option is primed if the drug's total sales value is deemed excessively high.

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...